Salvador Chulián

Mr. Salvador Chulián

University of Cádiz
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Communications in Nonlinear Science and Numerical Simulation
Verified
Journal Article
Closed access
OLOdelaisy León-Triana
Odelaisy León-Triana
SSSoukaina Sabir
Soukaina Sabir
Gabriel Fernandez CalvoGabriel Fernandez Calvo
Gabriel Fernandez Calvo
Juan Belmonte-BeitiaJuan Belmonte-Beitia
Juan Belmonte-Beitia
Salvador ChuliánSalvador Chulián
Salvador Chulián
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García

Verified
Journal Article
Open access
PDF file
Álvaro Martínez RubioÁlvaro Martínez Rubio
Álvaro Martínez Rubio
Salvador ChuliánSalvador Chulián
Salvador Chulián
CGCristina Blázquez Goñi
Cristina Blázquez Goñi
MRManuel Ramírez
Manuel Ramírez
Antonio Pérez MartínezAntonio Pérez Martínez
Antonio Pérez Martínez
Maria RosaMaria Rosa
Maria Rosa
Chimeric Antigen Receptor (CAR) T-cell therapy has demonstrated high rates of response in recurrent B-cell Acute Lymphoblastic Leukemia in children and young adults. Despite this success, a fraction of patients’ experience relapse after treatment. Relapse is often preceded by recovery of healthy B cells, which suggests loss or dysfunction of CAR T-cells in bone marrow. This site is harder to access, and thus is not monitored as frequently as peripheral blood. Understanding the interplay between B cells, leukemic cells, and CAR T-cells in bone marrow is paramount in ascertaining the causes of lack of response. In this paper, we put forward a mathematical model representing the interaction between constantly renewing B cells, CAR T-cells, and leukemic cells in the bone marrow. Our model accounts for the maturation dynamics of B cells and incorporates effector and memory CAR T-cells. The model provides a plausible description of the dynamics of the various cellular compartments in bone marrow after CAR T infusion. After exploration of the parameter space, we found that the dynamics of CAR T product and disease were independent of the dose injected, initial B-cell load, and leukemia burden. We also show theoretically the importance of CAR T product attributes in determining therapy outcome, and have studied a variety of possible response scenarios, including second dosage schemes. We conclude by setting out ideas for the refinement of the model.

3 May 2022 in SeMA Journal
Verified
Journal Article
Open access
PDF file
Salvador ChuliánSalvador Chulián
Salvador Chulián
Álvaro Martínez RubioÁlvaro Martínez Rubio
Álvaro Martínez Rubio
Maria RosaMaria Rosa
Maria Rosa
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Leukaemia accounts for around 3% of all cancer types diagnosed in adults, and is the most common type of cancer in children of paediatric age (typically ranging from 0 to 14 years). There is increasing interest in the use of mathematical models in oncology to draw inferences and make predictions, providing a complementary picture to experimental biomedical models. In this paper we recapitulate the state of the art of mathematical modelling of leukaemia growth dynamics, in time and response to treatment. We intend to describe the mathematical methodologies, the biological aspects taken into account in the modelling, and the conclusions of each study. This review is intended to provide researchers in the field with solid background material, in order to achieve further breakthroughs in the promising field of mathematical biology.

20 November 2023 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
TDThibault Delobel
Thibault Delobel
LALuis E. Ayala-Hernández
Luis E. Ayala-Hernández
JBJesús J. Bosque
Jesús J. Bosque
JPJulián Pérez-Beteta
Julián Pérez-Beteta
Salvador ChuliánSalvador Chulián
Salvador Chulián
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Low-grade gliomas are primary brain tumors that arise from glial cells and are usually treated with temozolomide (TMZ) as a chemotherapeutic option. They are often incurable, but patients have a prolonged survival. One of the shortcomings of the treatment is that patients eventually develop drug resistance. Recent findings show that persisters, cells that enter a dormancy state to resist treatment, play an important role in the development of resistance to TMZ. In this study we constructed a mathematical model of low-grade glioma response to TMZ incorporating a persister population. The model was able to describe the volumetric longitudinal dynamics, observed in routine FLAIR 3D sequences, of low-grade glioma patients acquiring TMZ resistance. We used the model to explore different TMZ administration protocols, first on virtual clones of real patients and afterwards on virtual patients preserving the relationships between parameters of real patients. In silico clinical trials showed that resistance development was deferred by protocols in which individual doses are administered after rest periods, rather than the 28-days cycle standard protocol. This led to median survival gains in virtual patients of more than 15 months when using resting periods between two and three weeks and agreed with recent experimental observations in animal models. Additionally, we tested adaptive variations of these new protocols, what showed a potential reduction in toxicity, but no survival gain. Our computational results highlight the need of further clinical trials that could obtain better results from treatment with TMZ in low grade gliomas.

23 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Salvador ChuliánSalvador Chulián
Salvador Chulián
Álvaro Martínez RubioÁlvaro Martínez Rubio
Álvaro Martínez Rubio
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Maria RosaMaria Rosa
Maria Rosa
CGCristina Blázquez Goñi
Cristina Blázquez Goñi
JFJ.L. Fernández-Martínez
J.L. Fernández-Martínez
Artificial intelligence methods may help in unveiling information that is hidden in high-dimensional oncological data. Flow cytometry studies of haematological malignancies provide quantitative data with the potential to be used for the construction of response biomarkers. Many computational methods from the bioinformatics toolbox can be applied to these data, but they have not been exploited in their full potential in leukaemias, specifically for the case of childhood B-cell Acute Lymphoblastic Leukaemia. In this paper, we analysed flow cytometry data that were obtained at diagnosis from 56 paediatric B-cell Acute Lymphoblastic Leukaemia patients from two local institutions. Our aim was to assess the prognostic potential of immunophenotypical marker expression intensity. We constructed classifiers that are based on the Fisher’s Ratio to quantify differences between patients with relapsing and non-relapsing disease. We also correlated this with genetic information. The main result that arises from the data was the association between subexpression of marker CD38 and the probability of relapse.

14 August 2023 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
Salvador ChuliánSalvador Chulián
Salvador Chulián
BSBernadette J. Stolz
Bernadette J. Stolz
Álvaro Martínez RubioÁlvaro Martínez Rubio
Álvaro Martínez Rubio
CGCristina Blázquez Goñi
Cristina Blázquez Goñi
JGJuan F. Rodríguez Gutiérrez
Juan F. Rodríguez Gutiérrez
HBHelen M. Byrne
Helen M. Byrne
Although children and adolescents with acute lymphoblastic leukaemia (ALL) have high survival rates, approximately 15-20% of patients relapse. Risk of relapse is routinely estimated at diagnosis by biological factors, including flow cytometry data. This high-dimensional data is typically manually assessed by projecting it onto a subset of biomarkers. Cell density and “empty spaces” in 2D projections of the data, i.e. regions devoid of cells, are then used for qualitative assessment. Here, we use topological data analysis (TDA), which quantifies shapes, including empty spaces, in data, to analyse pre-treatment ALL datasets with known patient outcomes. We combine these fully unsupervised analyses with Machine Learning (ML) to identify significant shape characteristics and demonstrate that they accurately predict risk of relapse, particularly for patients previously classified as ‘low risk’. We independently confirm the predictive power of CD10, CD20, CD38, and CD45 as biomarkers for ALL diagnosis. Based on our analyses, we propose three increasingly detailed prognostic pipelines for analysing flow cytometry data from ALL patients depending on technical and technological availability: 1. Visual inspection of specific biological features in biparametric projections of the data; 2. Computation of quantitative topological descriptors of such projections; 3. A combined analysis, using TDA and ML, in the four-parameter space defined by CD10, CD20, CD38 and CD45. Our analyses readily extend to other haematological malignancies.